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Anxiolytic-like effects observed in rats
exposed to the elevated zero-maze
following treatment with 5-HT2/5-HT3/
5-HT4 ligands
Rob Bell1, Aaron A. Duke2,3, Paula E. Gilmore1, Deaglan Page1 & Laurent Be`gue3
1School of Psychology, Queen’s University, Belfast, Northern Ireland, UK, 2Department of Psychology, University of Kentucky, USA,
3Department of Psychology, Grenoble-Alpes University, France.
The present study examined the effects of administering selective 5-HT antagonists and agonists to rats
tested in the elevated zero-maze (EZM) model of anxiety. The EZM paradigm has advantages over the
elevated plus-maze (EPM) paradigmwith respect tomeasuring anxiety, yet has been utilized less frequently.
Three experiments were conducted each with a diazepam control (0.25, 0.5 and 0.75 mg/kg). In the first
experiment, we administered the 5-HT2C antagonist RS 102221 (0.5, 1.0, and 2.0 mg/kg) and 5-HT2C
agonist MK-212 (0.25, 0.5 and 0.75 mg/kg); in the second experiment, we administered the 5-HT3
antagonist Y-25130 (0.1, 1.0 and 3.0 mg/kg) and 5-HT3 agonist SR 57227A (0.1, 1.0 and 3.0 mg/kg), and in
the third experiment, we administered the 5-HT4 antagonist RS 39604 (0.01, 0.1, 1.0 mg/kg) and 5-HT4
agonist RS 67333 (0.01, 0.1 and 0.5 mg/kg). The administration of 5-HT2/3/4 subtype antagonists all
generated behavioral profiles indicative of anxiolytic-like effects in the EZM, which was apparent from
examination of both traditional and ethological measures. While little effect was observed from 5-HT2 and
5-HT3 agonists, the 5-HT4 agonist RS 67333was found to produce a paradoxical anxiolytic-like effect similar
to that produced by the 5-HT4 antagonist RS 39604. We conclude by discussing the implications of these
findings.
I
nterest in the role of the 5-HT receptors in the control of anxiety first arose when clinical trials revealed an
anxiolytic-like effect of the non-selective 5-HT2 antagonist ritanserin in humans1. Since this time a number of
preclinical trials have been carried out, the majority of which have employed non-selective ligands. However,
an increasing awareness of the complexity of the 5-HT receptor family2 coupled with a number of equivocal
findings for non-selective 5-HT agents has led to great importance being placed upon the need to test the role of
specific 5-HT receptor subtypes in regulating anxiety.
Although preliminary studies employing animal models of anxiety have, in general, demonstrated that a
reduction in 5-HT neurotransmission plays a role in the effects of novel non-benzodiazepine anxiolytics3,
equivocal results for the effects of 5-HT subreceptor ligands have been reported, particularly in studies using
the elevated plus-maze paradigm (EPM)4. Inconsistent behavioral profiling of drugs that modulate the 5-HT
system led earlier investigators to query the utility of the EPMparadigm5; specifically, the predictive validity of the
EPM appears to be limited to benzodiazepine-related compounds6.
The elevated zero-maze (EZM) paradigm represents an important improvement over the EPM in that it
removes any ambiguity in the interpretation of time spent on the hub of the EPM and permits continuous
exploration7–9. The present paper will compare data obtained in our laboratory using 5-HT2, 5-HT3 and 5-
HT4 receptor ligands tested using the EZM paradigm with the results from other studies that have utilized similar
receptor ligands in a variety of preclinical models of anxiety. Specifically, we tested the effects of the 5-HT2C
antagonist RS-102221, the 5-HT2C agonist MK-212, the 5-HT3 antagonist Y-25130, the novel 5-HT3 agonist SR
57227A, the selective 5-HT4 antagonist RS 39604, and the high-affinity 5-HT4 partial agonist RS 67333.
The roles of 5-HT23, 5-HT310 and 5-HT4 receptors11 have been extensively reviewed in a variety of animal
models of anxiety. In addition, comprehensive reviews4,12–14 have examined, inter alia, strategies for experimental
modeling of anxiety, the validity of rodent models of anxiety and discussed the progression of such paradigms.
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Results
Combined descriptive statistics for the study variables including time
spent on open arms, open arm entries, head dips, SAP, risk assess-
ment, and rearing duration/frequency are presented in Table 1 along
with the correlations between aggregated study variables. Tables 2–4
respectively include the specific results for the three experiments.
Finally, Table 5 includes a summary of the direction of statistically
significant findings across all three experiments.
Experiment 1: 5-HT2 receptor ligands. Analyses revealed
significant variation in SAP, head dips, and risk assessment
behaviors across the various doses of diazepam. Conversely,
diazepam did not lead to significant variation in time spent on the
open arms of the maze, number of entries into the open arms, and
duration and frequency of rearing behaviors. Follow-up Mann-
Whitney U tests revealed an increased number of head dips for the
highest two doses (U 5 22.0, p, 0.05; U 5 2.0, p, 0.01). All three
doses of diazepamwere associated with reductions in SAP (U5 8.5, p
, 0.001;U 5 16.0, p, 0.01;U 5 5.5, p, 0.001) and risk assessment
(U 5 13.0, p , 0.01; U 5 18.0, p , 0.05; U 5 13.0, p , 0.01).
RS 102221 dose conditions produced significant variation with
respect to time spent on open arms, number of open arm entries,
SAP, head dips, and risk assessment. Follow-up post-hoc analyses
revealed that all doses of RS 102221 were associated with reduced
SAP (U5 9.5, p, 0.01;U5 3.0, p, 0.001;U5 2.0, p, 0.001) while
only the highest dose of 2.0 mg/kg was associated with increased
time on the open arms (U 5 22.5, p , 0.05), and head dips (U 5
10, p, 0.01). Analyses revealed a significant reduction in risk assess-
ment at both the 1.0 mg/kg (U5 17.0, p, 0.05) and 2.0 mg/kg (U5
13.0, p , 0.01) doses.
Significant variation was observed acrossMK-212 dose conditions
for rearing duration and rearing frequency. All doses were linked to
decreased rearing duration (U5 20.0, p, 0.05;U5 23.0, p, 0.05;U
5 5.0, p , 0.001) with the 0.25 mg/kg and 0.75 mg/kg doses being
Table 1 | Correlations between study variables and descriptive statistics for combined experiments
1 2 3 4 5 6 M SD
1. Time Open 48.5 32.7
2. Open Entries 0.86*** 5.5 3.7
3. Stretch Attend Posture 20.66*** 20.52** 6.2 3.6
4. Head Dips 0.82*** 0.77*** 20.68*** 7.8 3.5
5. Risk Assessment 20.81*** 20.68*** 0.80*** 20.73*** 25.4 21.3
6. Rearing Duration 0.28 0.29 20.08 0.26 20.25 11.5 4.0
7. Rearing Frequency 0.55** 0.54** 20.29 0.37* 20.47** 0.69*** 7.2 2.1
Notes. * p , 0.05, ** p , 0.01, *** p , 0.001.
Table 2 | Results from Experiment One
Diazepam
Behavior Saline Control 0.25 mg/kg 0.5 mg/kg 0.75 mg/kg H-values
Time Open 27.5 (0–52.8) 55.8 (17.6–74.5) 53.2 (20.4–90.5) 50.9 (35.7–82.5) 5.077
Open Entries 4.0 (0–6.8) 5.0 (1.0–8.5) 3.5 (1.0–5.5) 8.5 (5.5–11.3) 7.797
SAP 11.5 (7.8–14.5) 5.5 (2.8–7.3)*** 6.5 (4.8–9.3)** 4.0 (2.8–6.3)*** 17.414***
Head Dips 5.5 (3.8–7.0) 7.0 (4.0–11.0) 10.5 (5.3–13.3)* 12.5 (11.0–15.8)** 15.648**
Risk Assessment 50.7 (32.6–67.2) 17.4 (6.4–33.8)** 20.9 (11.9–30.1)* 12.6 (5.9–26.3)** 11.744**
Rearing Duration 13.8 (11.6–23.7) 11.3 (6.0–28.2) 10.3 (4.0–19.4) 10.9 (6.3–17.1) 2.405
Rearing Frequency 8.0 (7.0–8.3) 8.0 (3.0–10.5) 6.5 (3.0–9.5) 6.0 (4.0–7.3) 3.060
RS 102221
Behavior Saline Control 0.5 mg/kg 1.0 mg/kg 2.0 mg/kg H-values
Time Open 27.5 (0–52.8) 0.5 (0–52.8) 35.3 (0–78.0) 57.6 (30.9–92.6)* 8.550*
Open Entries 4.0 (0–6.8) 0 (0–1.0) 2.5 (0–10.3) 6.0 (1.8–9.3) 8.235*
SAP 11.5 (7.8–14.5) 3.5 (1.5–6.3)** 3.0 (1.5–4.3)*** 4.0 (1.8–5.3)*** 18.638***
Head Dips 5.5 (3.8–7.0) 3.5 (1.5–6.3) 7.0 (3.0–14.8) 14.5 (9.0–17.5)** 14.001**
Risk Assessment 50.7 (32.6–67.2) 46.8 (29.0–54.2) 10.3 (6.5–41.1)* 16.5 (4.5–30.9)** 12.495**
Rearing Duration 13.8 (11.6–23.7) 8.5 (1.7–15.1) 14.1 (6.6–19.8) 11.5 (6.0–20.1) 5.551
Rearing Frequency 8.0 (7.0–8.3) 5.5 (1.5–8.0) 6.5 (4.0–10.0) 6.5 (4.8–9.5) 5.865
MK-212
Behavior Saline Control 0.25 mg/kg 0.5 mg/kg 0.75 mg/kg H-values
Time Open 27.5 (0.0–52.8) 4.9 (0.0–58.1) 9.0 (0.0–28.3) 0.0 (0.0–35.0) 1.584
Open Entries 4.0 (0.0–6.8) 1.0 (0.0–4.0) 0.5 (0.5–3.0) 0.0 (0.0–1.0) 5.105
SAP 11.5 (7.8–14.5) 12.5 (10.0–18.8) 14.0 (5.2–18.2) 8.0 (5.5–9.5) 7.271
Head Dips 5.5 (3.8–7.0) 6.0 (3.5–7.2) 2.5 (0.0–6.0) 3.0 (1.5–4.8) 5.821
Risk Assessment 50.6 (32.6–67.2) 81.6 (45.8–112.0) 51.4 (35.9–75.8) 53.5 (33.9–63.7) 4.873
Rearing Duration 13.8 (11.6–23.7) 10.1 (5.2–13.9)* 8.8 (4.7–16.0)* 6.1 (1.1–10.2)* 12.684**
Rearing Frequency 8.0 (7.0–8.2) 4.5 (2.5–6.5)** 5.5 (0.5–3.0) 3.0 (0.8–6.0)** 13.973**
Notes. *, 0.05, **, 0.01, ***, 0.001, SAP 5 Stretched Attend Posture. Data expressed as medians (lower to upper quartiles), H-values based on Kruskal-Wallis, p-values based on Mann-Whitney U
post-hoc comparisons with the control condition. Each dose condition included 10 animals with a total of 100 animals included in the study.
www.nature.com/scientificreports
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also linked to decreased rearing frequency (U 5 15.0, p, 0.01; U 5
2.0, p , 0.001).
Experiment 2: 5-HT3 receptor ligands. Analyses revealed that the
highest dose of diazepam (0.75 mg/kg) significantly decreased
the duration of risk assessment behavior (U 5 16.0, p , 0.01). The
highest two doses of diazepam (0.5 mg/kg and 0.75 mg/kg) were
associated with decreased SAP (U 5 22.0, p , 0.05; U 5 17.5, p ,
0.05) and the 0.5 mg/kg dose was also associated with increased head
dips (U 5 23.5, p , 0.05).
While no significant differences were observed for the 0.1 mg/kg
and 3.0 mg/kg doses of Y-25130, a number of effects were observed
for themoderate 1.0 mg/kg dose. Specifically, the 1.0 mg/kgY-25130
dose was associated with significantly increased time spent in the
open arms (U 5 17.0, p , 0.05) and a greater number of open arm
entries (U 5 17.5, p , 0.05). Additionally, this dose was associated
with decreased SAP (U 5 23.0, p, 0.05), decreased risk assessment
(U 5 16.0, p, 0.01), and increased head dips (U 5 23.0, p, 0.05).
Mann-Whitney U analysis revealed that the moderate dose of SR
57227A (1.0 mg/kg) was associated with a significant increase in risk
assessment (U 5 16.0, p , 0.01). No other statistically significant
effects were observed across the 0.1 mg/kg and 3.0 mg/kg doses of SR
57227A.
Experiment 3: 5-HT4 receptor ligands. Post-hoc analysis revealed
that both the 0.5 and 0.75 mg/kg doses of diazepam significantly
increased time spent on open arms (U 5 11.0, p , 0.01; U 5 13.0,
p , 0.01), number of open arm entries (U 5 23.5, p , 0.001; U 5
23.5, p , 0.05), and number of head dips (U 5 9.0, p , 0.01; U 5
19.0, p , 0.05), while significantly decreasing duration of risk
assessment behavior (U 5 8.0, p , 0.01; U 5 18.0, p , 0.05).
Additionally, the 0.75 mg/kg dose was linked to decreased rearing
duration (U 5 21.5, p , 0.05).
Mann-WhitneyU analysis revealed that all doses of RS 39604 were
associated with significant increases in time spent on open arms (U
5 1.0, p, 0.01; U 5 8.0, p, 0.01; U 5 6.0, p, 0.01) an increased
number of open arm entries (U 5 14.3, p, 0.01;U 5 15.0, p, 0.01;
U 5 6.0, p, 0.01), increased head dips (U 5 5.0, p, 0.01;U 5 13.5,
p , 0.01; U 5 12.5, p , 0.01), and significantly decreased risk
assessment (U 5 3.0, p, 0.01;U 5 5.0, p, 0.01;U 5 5.0, p, 0.01).
Analyses revealed that all doses of RS 67333 were associated with
an increased number of open arm entries (U 5 9.0, p , 0.01; U 5
23.0, p , 0.05; U 5 23.5, p , 0.05) and decreased risk assessment
duration (U 5 3.0, p, 0.01; U 5 6.0, p, 0.01; U 5 20.5, p, 0.01).
Furthermore, both the 0.01 mg/kg and 0.1 mg/kg doses of RS 67333
were linked to increased head dips (U5 10.5, p, 0.01;U5 12.0, p,
0.01) and time spent on the open arms of the maze (U 5 13.0, p ,
0.01; U 5 11.0, p , 0.01).
Discussion
While both the 0.5 and 1.0 mg/kg doses of the 5-HT2C antagonist RS
102221 failed to significantly modify spatio-temporal measures in
the current experiment, the 2.0 mg/kg dose of this drug significantly
increased time spent on the open arms of the EZM. This pattern of
effects suggests a possible anxiolytic role for higher doses of RS
102221. Consistent with this interpretation, an ethological measure
indicative of reduced anxiety (i.e., head dips) was significantly
increased only at the 2.0 mg/kg dose. While one earlier experiment
failed to find any anxiolytic effects for the 5-HT2A/2C antagonist
ketanserin3, our outcome is consistent with an earlier report of an
anxiolytic-like effect of the 5-HT2B/2C antagonist SB 200646A27 and
Table 3 | Results from Experiment Two
Diazepam
Behavior Saline Control 0.25 mg/kg 0.5 mg/kg 0.75 mg/kg H-values
Time Open 34.1 (5.0–83.0) 11.0 (0.0–26.3) 80.8 (21.0–114.7) 61.8 (13.5–87.6) 8.679*
Open Entries 4.0 (0.8–8.5) 1.5 (0.0–5.0) 9.5 (1.5–13.2) 6.5 (2.8–10.2) 4.835
SAP 8.5 (4.0–11.2) 7.5 (5.0–10.0) 4.0 (1.8–5.2)* 2.0 (0.8–5.0)* 13.890**
Head Dips 5.5 (2.8–8.2) 3.5 (2.0–5.2) 12.5 (6.5–17.0)* 8.5 (6.0–10.5) 14.109**
Risk Assessment 26.4 (11.0–42.0) 55.2 (36.0–63.6) 10.6 (0.0–17.9) 4.0 (0.0–17.0)** 17.218***
Rearing Duration 11.8 (6.4–27.3) 6.6 (2.9–19.2) 12.8 (8.8–19.9) 6.8 (2.4–18.4) 2.483
Rearing Frequency 7.0 (4.0–8.2) 5.0 (1.0–8.0) 6.5 (4.8–11.0) 5.0 (2.0–13.2) 2.490
Y-25130
Behavior Saline Control 0.1 mg/kg 1.0 mg/kg 3.0 mg/kg H-values
Time Open 34.1 (5.0–83.0) 18.4 (18.2–28.5) 97.5 (83.2–32.8)* 43.0 (16.5–70.6) 13.267**
Open Entries 4.0 (0.8–8.5) 4.0 (2.8–7.2) 7.0 (5.0–12.0)* 7.0 (1.5–9.8) 16.487**
SAP 8.5 (4.0–11.2) 9.5 (8.5–11.0) 4.0 (3.0–5.0)* 7.5 (4.0–11.2) 12.880**
Head Dips 5.5 (2.8–8.2) 4.0 (2.8–7.2) 11.0 (9.0–12.2)* 9.5 (1.0–13.2) 8.745*
Risk Assessment 11.8 (6.4–27.3) 44.6 (24.8–66.0) 8.0 (0.0–12.9)** 14.7 (6.7–29.0) 16.584***
Rearing Duration 26.4 (11.0–42.0) 12.9 (12.2–14.2) 15.0 (11.4–18.2) 19.8 (15.3–23.3) 3.760
Rearing Frequency 7.0 (4.0–8.2) 9.5 (6.8–10.2) 9.0 (7.8–11.0) 8.5 (7.0–12.0) 6.352
SR 57227A
Behavior Saline Control 0.1 mg/kg 1.0 mg/kg 3.0 mg/kg H-values
Time Open 34.1 (5.0–83.0) 65.0 (27.6–101.9) 35.7 (21.4–70.3) 2.3 (0.0–51.8) 8.477*
Open Entries 4.0 (0.8–8.5) 9.0 (3.2–13.5) 8.0 (2.8–9.5) 1.0 (0.0–12.2) 5.668
SAP 8.5 (4.0–11.2) 8.5 (5.5–14.2) 13.0 (9.5–17.2) 10.0 (5.8–14.2) 5.943
Head Dips 5.5 (2.8–8.2) 6.5 (6.0–14.5) 5.0 (2.0–6.0) 2.5 (1.0–4.8) 11.106*
Risk Assessment 11.8 (6.4–27.3) 24.6 (5.4–56.7) 53.2 (44.1–77.8)** 20.8 (15.7–46.2) 9.075*
Rearing Duration 26.4 (11.0–42.0) 12.2 (7.0–18.7) 7.4 (5.0–9.6) 7.1 (3.9–10.3) 5.808
Rearing Frequency 7.0 (4.0–8.2) 7.5 (6.8–9.2) 5.0 (3.8–6.2) 5.5 (3.5–7.0) 8.114*
Notes. *, 0.05, **, 0.01, ***, 0.001, SAP 5 Stretched Attend Posture. Data expressed as medians (lower to upper quartiles), H-values based on Kruskal-Wallis, p-values based on Mann-Whitney U
post-hoc comparisons with the control condition. Each dose condition included 10 animals with a total of 100 animals included in the study.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 3881 | DOI: 10.1038/srep03881 3
other reports of anxiolytic-like action of 5-HT2C blockade in animal
models of anxiety28.
An examination of traditional measures of anxiety revealed a gen-
eral lack of effect for the selective 5-HT2C agonist MK-212. However,
MK-212 was found to significantly reduce the duration of rearing at
all doses and to significantly reduce the frequency of rearing at both
the lowest and highest doses tested. Factor analysis has found rearing
to load on a ‘motor activity’ factor in the EPM29 suggesting the
possibility that the general lack of effects observed after MK-212
administrationmay have been due to behavioral inhibition/sedation.
Overall, these findings are in agreement with a number of previous
studies which also report a general lack of effect of 5-HT2 agonism in
animal models of anxiety3,30,31.
The finding that the 1.0 mg/kg dose of Y-25130 increased both
time spent on the open arms and total arm entries is in agreement
with previous studies examining the effects of 5-HT3 antagonism on
traditionalmeasures in both the EPMand EZM32,33 and is compatible
with an anxiolytic-like profile comparable to that obtained with dia-
zepam. Consistent evidence for this interpretation was also observed
from ethological measures with the 1.0 mg/kg dose leading to
decreased SAP and risk assessment in conjunction with increased
head dips. This latter finding is also in agreement with previous
studies including work with the EPM34, social interaction test35,
and light-dark test17, in suggesting an anxiolytic effect of 5-HT3
antagonists in animals. However, it should be noted that these effects
were not observed for the smaller (0.1 mg/kg) and larger (3.0 mg/kg)
doses suggesting the possibility of a hormetic dose-response curve.
While the 5-HT3 agonist SR 57227A was found to significantly
modify most anxiety-related behaviors as measured in the EZM,
examination of the effects of specific doses revealed a general lack
of significant effects when compared to the saline control condition.
The 0.1 mg/kg dose of this drug failed to modify any behavioral
measures, although the general pattern of results, which include
non-significant increases in behavior associated with both anxiogen-
esis and anxiolysis, would suggest non-specific effects.
The 5-HT4 antagonist RS 39604 significantly increased both time
spent on the open arms and total arm entries in a manner consistent
with anxiolysis. These findings are in agreement with those of
Silvestre and colleagues11 as well as Kennett and colleagues28,36 who
previously reported an anxiolytic-like effect of the 5-HT4 antagonists
GR 113808, SB 204070, SB 204070A, and SB 207266A on traditional
measures in the EPM. With respect to ethological measures, RS
39604 was found to increase head dips and reduce risk assessment,
but failed to modify SAP. Overall, RS 39604 was found tomodify less
anxiety-related behaviors than diazepam in the current experiment.
This finding is again in agreement with the work of Silvestre et al.11
and Kennett et al.28,36, both of whom reported that the effects of 5-
HT4 antagonists were smaller than those of either diazepam or
chlordiazepoxide in the EPM, leading both authors to conclude that
5-HT4 antagonists have modest anxiolytic-like activity when com-
pared with the benzodiazepines.
The 5-HT4 agonist RS 67333 was found to increase both time on
the open arm of the EZM and to increase the number of entries onto
open arms, a profile consistent with anxiolysis. This interpretation is
further supported by ethological measures (i.e., all doses resulted in a
reduction in risk assessment with the 0.01 mg/kg and 0.1 mg/kg
doses were associated with an increase in head dips). While this
finding is in agreement with previous findings in suggesting that 5-
HT4 agonism is associated with a decrease in anxiety-induced beha-
vioral inhibition37, the result is surprising in light of the finding that
Table 4 | Results from Experiment Three
Diazepam
Behavior Saline Control 0.25 mg/kg 0.5 mg/kg 0.75 mg/kg H-values
Time Open 13.5 (0.0–40.8) 39.7 (20.9–53.6) 68.6 (50.1–120.7)** 75.8 (28.6–84.4)** 14.93**
Open Entries 1.0 (0.0–4.2) 4.5 (2.0–7.2) 12.5 (6.8–13.2)*** 6.5 (1.8–9.0)* 14.44**
SAP 8.0 (1.0–11.2) 5.0 (3.0–10.0) 2.0 (0.8–4.0) 1.0 (0.0–3.8)* 9.01*
Head Dips 3.0 (2.8–5.8) 9.0 (3.0–12.2) 11.0 (7.0–15.8)** 10.5 (4.8–12.5)* 11.08*
Risk Assessment 52.2 (33.8–83.6) 22.6 (13.6–53.8) 8.8 (0.4–23.7) *** 4.6 (0.0–43.8)* 13.15**
Rearing Duration 15.6 (5.4–29.6) 16.2 (11.2–21.6) 11.2 (5.4–21.4) 4.8 (1.7–9.6)* 8.66*
Rearing Frequency 7.5 (4.0–9.2) 9.5 (7.2–11.0) 8.0 (4.8–10.2) 3.5 (1.8–5.5) 9.51*
RS 39604
Behavior Saline Control 0.01 mg/kg 0.1 mg/kg 1.0 mg/kg H-values
Time Open 13.5 (0.0–40.8) 126.1 (103.8–163.7)** 88.8 (63.5–123.6)** 82.8 (57.8–109.9)** 23.19***
Open Entries 1.0 (0.0–4.2) 14.0 (12.8–17.5)*** 7.0 (3.8–9.5)** 10.0 (7.8–12.5)*** 26.52***
SAP 8.0 (1.0–11.2) 2.0 (0.0–5.2) 4.0 (3.8–5.0) 4.0 (2.8–6.2) 7.42
Head Dips 3.0 (2.8–5.8) 14.5 (11.0–16.5)*** 8.5 (6.8–10.2)** 9.5 (6.0–10.2)** 18.76***
Risk Assessment 52.2 (33.8–83.6) 2.0 (0.0–9.7)** 4.3 (0.0–11.3)** 5.9 (2.3–15.5)** 19.47***
Rearing Duration 15.6 (5.4–29.6) 12.8 (9.2–23.2) 18.7 (8.3–24.2) 18.8 (11.7–22.5) 0.56
Rearing Frequency 7.5 (4.0–9.2) 10.0 (5.5–15.5) 9.0 (7.0–11.2) 11.0 (9.5–14.2) 6.61
RS 67333
Behavior Saline Control 0.01 mg/kg 0.1 mg/kg 0.5 mg/kg H-values
Time Open 13.5 (0.0–40.8) 79.8 (41.0–103.2)** 82.2 (40.0–100.6)** 53.6 (21.0–83.8) 12.58**
Open Entries 1.0 (0.0–4.2) 10.0 (7.8–14.5)** 6.5 (2.0–10.2)* 5.5 (3.2–9.5)* 13.11**
SAP 8.0 (1.0–11.2) 2.0 (1.8–3.2) 3.5 (2.8–4.2) 8.0 (3.8–10.5) 8.88
Head Dips 3.0 (2.8–5.8) 10.5 (9.2–12.5)** 9.0 (7.8–11.2)** 8.0 (6.0–11.0) 12.48**
Risk Assessment 52.2 (33.8–83.6) 0.4 (0.0–0.6)* 9.2 (3.3–15.1)* 27.2 (13.7–38.1)* 23.57***
Rearing Duration 15.6 (5.4–29.6) 12.4 (5.4–17.2) 5.0 (2.9–13.6) 12.4 (8.8–17.3) 5.43
Rearing Frequency 7.5 (4.0–9.2) 12.0 (6.0–15.0) 8.5 (5.2–11.2) 7.5 (5.8–9.8) 2.66
Notes. *, 0.05, **, 0.01, ***, 0.001, SAP 5 Stretched Attend Posture. Data expressed as medians (lower to upper quartiles), H-values based on Kruskal-Wallis, p-values based on Mann-Whitney U
post-hoc comparisons with the control condition. Each dose condition included 10 animals with a total of 100 animals included in the study.
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5-HT4 antagonism led to a similar anxiolytic profile. One possible
explanation for this seeming paradox is a non-rectilinear relation
between 5-HT4 activity and anxiety. An inverted-U shaped anxioly-
tic profile would be sensitive to 5-HT4 disruptions whether they were
in the form of increased or decreased 5-HT4 activation. However,
further research will be necessary to develop this possibility.
In conclusion, results from this study indicate a potential role for
5-HT2, and 5-HT3 antagonists and an apparently paradoxical role for
both 5-HT4 agonists and 5-HT4 antagonists in producing anxiolytic-
like effects on rats tested in the EZM paradigm. Such results from the
use of the EZM can be compared to data from the EPM that is
considered comparable following diazepam challenge, although the
more direct measure of time spent in the open may represent an
advantage of the elevated zero-maze7.
The results for the 5-HT2, 5-HT3 and 5-HT4 antagonists employed
in our experiments are consistent with the original hypothesis for the
role of serotonin in the pathogenesis of anxiety that was predicated
on an association between a reduction in 5-HT turnover and the
anxiolytic effects of benzodiazepines suggesting that a reduction of
5-HT neurotransmission results in an anxiolytic-like effect, whereas
increased activity produces an anxiogenic-like effect38. Notwith-
standing this conclusion, the behavioral pharmacology of 5-HT
receptor ligands is often more inconsistent than the effects of stand-
ard anxiolytics and not all results are explainable in terms of the
classic hypothesis, as evinced in our third experiment that demon-
strated an anxiolytic-like effect with a compound that increased
serotonergic activity.
Moreover, it should be noted standard anxiolytics (e.g., diazepam)
sometimes produce counter-intuitive results as well such as the find-
ing in Experiment 2 (see Table 3) that the low dose of diazepam was
associated with less time spent on the open arms of the EZM than the
saline control condition. Given that data for these groups were
collected over a time span of 18 months, we postulated that such
variations may, in part, be due to circadian rhythm effects.
Benzodiazepines, such as diazepam, are thought to act by potentiat-
ing the action of the neurotransmitter c-aminobutyric acid, which in
turn, has been linked to regulation of the sleep-wake cycle39. Hence,
the variations in responses to diazepam may be the result of the
benzodiazepine acting at varying levels of GABA that mediate the
generation of circadian rhythms.
A dual role for 5-HT in the mediation of different types of fear has
been posited by Graeff and Zangrossi40. Specifically, serotonin may
either enhance or reduce anxiety-like behavior depending upon the
receptor subtype involved. Indeed, the fact that selective serotonin
reuptake inhibitors are efficacious in the treatment of generalized
anxiety disorder and in panic disorder indicates that there are con-
ditions in which increased 5-HT activity can reduce anxiety.
Methods
Animals. All work was licensed by the Home Office via the Northern Ireland
Department of Health, Social Services and Public Safety in accordance with the UK
Animals (Scientific Procedures) Act 1986 and was in full compliance with Queen’s
University Belfast’s Policy on theUse of Animals in Research and Teaching. In each of
the three experiments, one hundred male Sprague-Dawley rats were randomly
assigned as follows: saline control (n5 10), diazepam (n5 30), 5-HT antagonist (n5
30), and 5-HT agonist (n 5 30). Animals were supplied from a breeding stock at
Queen’s University and weighing between 280 and 350 grams were group-housed (5
per cage; cage size 51 3 39 3 19 cm) in a temperature-controlled environment 22 6
1uC under a 12-hour reverse light-dark cycle (lights off at 0800 hours) for four weeks
prior to testing and prior to experimentation has been handled only for routine
husbandry. Food and water were available ad libitum. All animals were both drug and
experimentally naive.
Table 5 | Summary of significant findings across three experimental studies relative to saline controls
Drug Dose
Open Arms
SAP Head Risk
Rearing
(mg/kg) Time Entries Dips Assessment Duration Frequency
Experiment One
Diazepam 0.25 - - # - # - -
Diazepam 0.50 - - # " # - -
Diazepam 0.75 - - # " # - -
RS 102221 0.50 - - # - - - -
RS 102221 1.0 - - # - # - -
RS 102221 2.0 " - # " # - -
MK-212 0.25 - - - - - # #
MK-212 0.50 - - - - - # -
MK-212 0.75 - - - - - # #
Experiment Two
Diazepam 0.25 - - - - - - -
Diazepam 0.50 - - # " - - -
Diazepam 0.75 - - # - # - -
Y-25130 0.1 - - - - - - -
Y-25130 1.0 " " # " # - -
Y-25130 3.0 - - - - - - -
SR57227A 0.1 - - - - - - -
SR57227A 1.0 - - - - " - -
SR57227A 3.0 - - - - - - -
Experiment Three
Diazepam 0.25 - - - - - - -
Diazepam 0.50 " - - " # - -
Diazepam 0.75 " - # " # # -
RS 39604 0.01 " " - " # - -
RS 39604 0.1 " " - " # - -
RS 39604 1.0 " " - " # - -
RS 67333 0.01 " " - " # - -
RS 67333 0.1 " " - " # - -
RS 67333 0.5 - " - - # - -
Notes. SAP 5 Stretched Attend Posture, "5 increased behaviour (compared to saline control) as detected by Mann-WhitneyUwhen Kruskal WallisH-value,0.05, #5 decreased behaviour (compared to
saline control) as detected by Mann-Whitney U when Kruskal Wallis H-value , 0.05.
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Apparatus. The design of the maze employed was based on that originally proposed
by Shepherd et al.9 and consists of a black Perspex annular platform, 105 cm in
diameter and 10 cm wide, elevated 65 cm above the ground. The maze was divided
into four equal quadrants, two of which were enclosed with black Perspex walls,
27 cm in height. Thewalls were on both the inner and outer sides of the platform so as
to provide the ‘closed’ areas of the maze. The ‘open’ arms had no walls, but did have a
1 cm lip which acts as a tactile aid to animals when on the open areas of the maze.
Lighting was provided by two 60 watt red ceiling lights at a height of 2 m positioned
directly over the maze and one 60 watt red bulb positioned closer to the maze. Two
cameras poised at 45-degree angles were positioned 1 m above the ground and 1 m
from either side of the maze. The cameras were connected to a multiplexer in an
adjacent laboratory in order to prevent distractions and provided continuous
recording of behavior for subsequent analysis.
Drugs. All of the active compounds–MK-212 (0.25–0.75 mg/kg), RS 102221 (0.5–
2.0 mg/kg), SR 57227A (0.1–3.0 mg/kg), Y-25130 (0.1–3.0 mg/kg), RS 67333 (0.01–
0.5 mg/kg), RS 39604 (0.01–1.0 mg/kg), and the positive comparator, diazepam
(0.25–0.75 mg/kg), were obtained fromTocrais CooksonUK. The dose ranges for the
drugs were chosen from the experimental pharmacology literature examining the
relation between 5-HT and anxiety3,4,15–20. All compounds were prepared as solutions
or suspensions in physiological vehicle. Saline alone was administered to control
animals and diazepam was used as a positive control. All solutions were freshly
prepared on the day of testing and administered intraperitoneally (1 ml/kg) 30
minutes prior to testing.
Procedure. All testing was conducted between 0800 and 1400 hours. On the day of
testing one animal was selected and transferred in a covered box (to maintain
darkness) measuring 32 3 16 3 12.5 cm to a room adjacent to the experimental
room. Here a subcutaneous (s.c) injection was administered under red light and the
animal was placed in a cage measuring 40.5 3 28 3 12 cm containing only sawdust
bedding (i.e., no food and water). The animal remained in this staging cage for 30
minutes in order to allow adequate absorption of drug, after which time the animal
was transferred to the experimental room (again in a darkened box) and placed on the
zero-maze at a junction between an open and closed arm, facing into the closed area.
Each animal was placed on an alternative side of the maze so as to avoid any bias. All
testing was conducted under red-light. After 5minutes, the animal was removed from
the maze and the maze was washed using an ethanol/water solution so as to avoid
olfactory cues transferring from one experimental session to the next. Once testing
was complete, computer-based event recording and ethological analysis software
(Hindsight ver. 1.5) was used to register the relevant experimental variables.
Videotapes were scored blindly by a highly trained observer (intra-observer reliability
. 0.8). Behavioral parameters comprised traditional spatio-temporal, locomotion,
maintenance and ethological measures21–23, which are outlined below.
Measures. Spatio-temporal measures. Traditional spatio-temporal measures included
(a) time on open arms and (b) frequency of open arm entries. The animal was judged
to enter into the open arm area of the maze when all four paws crossed the open arm
threshold. After crossing into the open arm area, the animal was allowed to have one
paw in the closed area of themaze and still be considered in the open area; however, if
two paws crossed the threshold, then they were judged to have re-entered the closed
area of the maze9,24.
Ethological measures. Stretched Attend Posture was defined as the frequency with
which the animal makes a forward elongation of the head and shoulders followed by a
retraction to the original position when the animal is on an open arm23. Head dips
measured the frequency of the animal protruding its head over the ledge of an open
arm and down towards the floor25. Finally, Risk Assessment was scored as the fre-
quency of an animal exiting a closed arm of the maze with forepaws and head only,
and investigating the surroundings. Risk assessment was scored independently of
stretch attend posture, which often accompanied risk assessment21.
Locomotion andmaintenancemeasures.Rearing Frequencywas defined as the number
of verticalmovements against the side or end ofwalls of the closed arms of themaze or
raising up its hind paws sans support in the open area of themaze26.Rearing Duration
measured the time each animal was engaged in rearing behavior.
Analysis.Data for each behavioral element were grouped according to treatment and
were initially checked for normality and homogeneity of variance. Levene’s tests were
statistically significant (i.e. assumptions that distributions were normal or variances
were equal had to be rejected); therefore, non-parametric tests were conducted (as
opposed to data transformation). Data were analyzed using Kruskal-Wallis
nonparametric one-way analysis of variance across treatment groups. Where
significant variations in the data were identified, post-hoc Mann-Whitney U
comparisons with control condition were performed. In all cases, a standard
significance level a was set at p 5 0.05.
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